Author

B. Balakrishnan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Bioengineering· 1 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Organism:human· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

L. Zhang· 2 shared N. Packiriswamy· 2 shared R. Narjari· 2 shared R. Vandergaast· 2 shared S. J. Russell· 2 shared A. Baum· 1 shared A. Garcia-Sastre· 1 shared A. Gorantla· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

L. Zhang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants.

M. A. Munoz Alia, R. A. Nace, B. Balakrishnan, L. Zhang, N. Packiriswamy, G. Singh, P. Warang, I. Mena, R. Narjari, R. Vandergaast, A. Garcia-Sastre, M. Schotsaert, S. J. Russell

This study develops a measles-based vaccine encoding SARS-CoV-2 spike glycoproteins that enhances neutralizing antibody responses against both omicron and historical variants.

mBio · Feb 14, 2024Peer-reviewedMicrobiology

Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable In Situ Cross-Linked Depots

S. Lee, S. Zhao, W. Jiang, X. Chen, L. Zhu, J. Joseph, E. Agus, H. B. Mary, S. Barooj, K. Slaughter, K. Cheung, J. N. Luo, C. Shukla, J. Gao, D. Lee, , N. Joshi

This paper develops an injectable platform for ultra-long-term hydrophilic drug delivery, achieving sustained release over six months in vivo.

bioRxiv · Nov 4, 2023 · PreprintBioengineering

Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine

K. W. Peng, T. Carey, P. Lech, R. Vandergaast, M. A. Munoz-Alia, N. Packiriswamy, C. Gnanadurai, K. Krotova, M. Tesfay, C. Ziegler, M. Haselton, K. Sevola, C. Lathrum, S. Reiter, R. Narjari, , S. J. Russell

This study develops an oral rhabdoviral vaccine that boosts SARS-CoV-2 immunity in nonhuman primates by enhancing viral tropism through G protein trans-complementation.

bioRxiv · Oct 16, 2021Immunology

Modulation of SARS-CoV-2 Spike-induced Unfolded Protein Response (UPR) in HEK293T cells by selected small chemical molecules

B. Balakrishnan, K. Lai

The paper investigates how selected small molecules modulate the UPR in HEK293T cells overexpressing SARS-CoV-2 Spike protein, finding that PBA and TUDCA reduce peIF2 and autophagy levels.

bioRxiv · Feb 4, 2021 · PreprintBiochemistry